EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

Mónica López-Lacort, Ana Corberán-Vallet, Francisco J Santonja, Cintia Muñoz-Quiles, Javier Díez-Domingo, Alejandro Orrico-Sánchez

Journal of Infection and Public Health · 2024

DOI: 10.1016/j.jiph.2024.102492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Infection and Public Health, 2024. Verfasst von Mónica López-Lacort und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Unit, Fisabio, Public Health, Avenida Cataluña 21, 46020 Valencia, Spain; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain. El…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Hospitalization. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, AstraZeneca, Sanofi Pasteur SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis. METHODS: Population-based real-world data from primary care and hospitalizations were considered. RSV bronchiolitis dynamics in absence of these immunization scenarios were explained by a multivariate age-structured Bayesian model. Then, the potential impact was simulated under different assumptions including the most recent clinical trial data. Differences in endpoints, populations, and timeframes between trials make the two products' efficacy difficult to compare. RESULTS: A seasonal with catch-up program, assuming a constant effectiveness of 79.5 % during the first 5 months followed by a linear decay to 0 by month 10 with nirsevimab, would prevent between 5121 and 8846 RSV bronchiolitis per 100,000 infants-years. Assuming 77.3 % effectiveness with the same decay, between 976 and 1686 RSV-hospitalizations per 100,000 infants-years could be prevented depending on the uptake. A year-round maternal immunization program, with 51 % of effectiveness during the first 6 months followed by a linear decay to 0 by month 10 would prevent between 3246 and 5606 RSV bronchiolitis cases per 100,000 infants-years. Assuming 56.9 % effectiveness with the same decay, between 713 and 1231 RSV-hospitalizations per 100,000 infants-years could be prevented. CONCLUSIONS: Our results suggest that each strategy would effectively reduce RSV-bronchiolitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesHospitalizationHumansInfantFemaleMaleBronchiolitisBronchiolitis, ViralAntibodies, Monoclonal, HumanizedInfant, NewbornImmunization ProgramsAntibodies, Monoclonal

Stichwörter der Autor:innen

Bayesian modellingMaternal immunizationNirsevimabRSV

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Vaccine Research Unit, Fisabio, Public Health, Avenida Cataluña 21, 46020 Valencia, Spain; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: monica.lopez@fisabio.es.
  • Statistics and Operational Research Department, University of Valencia, Calle del Dr. Moliner 50, 46100 Burjassot, Valencia, Spain.
  • Vaccine Research Unit, Fisabio, Public Health, Avenida Cataluña 21, 46020 Valencia, Spain; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.
  • Vaccine Research Unit, Fisabio, Public Health, Avenida Cataluña 21, 46020 Valencia, Spain; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain; Universidad Católica de Valencia, Spain.

Förderung

  • Sanofi
  • AstraZeneca
  • Sanofi Pasteur SA

Zitieren

APA

López-Lacort, M., Corberán-Vallet, A., Santonja, F. J., Muñoz-Quiles, C., Díez-Domingo, J., & Orrico-Sánchez, A. (2024). Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2024.102492

Vancouver

López-Lacort M, Corberán-Vallet A, Santonja FJ, Muñoz-Quiles C, Díez-Domingo J, Orrico-Sánchez A. Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study. Journal of Infection and Public Health. 2024. doi:10.1016/j.jiph.2024.102492

BibTeX
@article{LpezLacort2024,
  author = {López-Lacort, Mónica and Corberán-Vallet, Ana and Santonja, Francisco J and Muñoz-Quiles, Cintia and Díez-Domingo, Javier and Orrico-Sánchez, Alejandro},
  title = {Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study},
  journal = {Journal of Infection and Public Health},
  year = {2024},
  doi = {10.1016/j.jiph.2024.102492}
}
Kostenlos starten →